Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
arm, article, biomarker, cell, encompassing, Expert, fatigue, IgG, IgM, immaterial, immunological, Institutional, Israel, Latin, liprotomase, mg, Michele, Morton, NOL, nonclinical, Petri, PHSA, predefined, Professor, Scheinberg, screening, SPC, statistical, tendency, week
Removed:
allocation, Assuming, barred, Eastern, qualifying, randomization
Filing tables
Filing exhibits
Related press release
ANTH similar filings
Filing view
External links
Exhibit 32.2
Certification Pursuant to
Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350
I, May Liu, certify, pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Anthera Pharmaceuticals, Inc. on Form 10-Q for the quarter ended June 30, 2016 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Anthera Pharmaceuticals, Inc.
By: | /s/ May Liu | ||
Name: | May Liu | ||
Title: | Senior Vice President, Finance and Administration (Principal Accounting Officer) | ||
Date: August 9, 2016 |